| Literature DB >> 29747479 |
Mohammed A Al-Omair1, Abdelwahed R Sayed2,3, Magdy M Youssef4,5.
Abstract
Small heterocyclic compounds containing nitrogen andEntities:
Keywords: DNA degradation; IC50; antimicrobial; antioxidant; hydrazonoyl; polythiazoles; thiazoles; thiosemicarbazones
Mesh:
Substances:
Year: 2018 PMID: 29747479 PMCID: PMC6099618 DOI: 10.3390/molecules23051133
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Scheme 1Synthesis of bisthiazoles 4a, 4b, and 5.
Scheme 2Synthesis of bisthiazoles 7a, 7b, and 8.
Scheme 3Synthesis of bisthiazole 13 and polythiazoles 11 and 12.
Figure 1A figure showing the degradation effect of 2 (A), 4 (B), 6 (C), 8 (D), and 10 (E) µM of compounds (1, 4a, 4b, 5, 6, 7a, 7b, 8, 9, 11, 12, and 13) (Lanes 3–14) on the genomic DNA isolated from E. coli. Lane 1 E. coli DNA; Lane 2 E. coli DNA + DMSO.
Antioxidant activity assay (ABTS) of the tested compounds.
| Compound No. | % Inhibition |
|---|---|
| Control of ABTS | - |
| Ascorbic acid | 86.2 |
|
| 67.4 |
|
| 61.2 |
|
| 53.7 |
|
| 51.9 |
|
| 60.1 |
|
| 51.2 |
|
| 50.3 |
|
| 48.1 |
|
| 49.4 |
|
| 58.5 |
|
| 63.7 |
|
| 56.1 |
Figure 2The nitric oxide scavenging activity of the tested compounds.
Figure 3The activity of the tested compounds against lipid peroxidation.
Effect of novel compounds on Gram-negative and Gram-positive microorganisms. The results are expressed as zone inhibition in mm diameter.
| Compound | Gram-Negative | Gram-Positive | ||
|---|---|---|---|---|
|
|
|
|
| |
|
| 17 | 16 | 17 | 16 |
|
| 16 | 15 | 16 | 16 |
|
| 12 | 11 | 14 | 12 |
|
| 12 | 12 | 11 | 10 |
|
| 15 | 15 | 14 | 15 |
|
| 13 | 12 | 13 | 12 |
|
| 12 | 12 | 11 | 11 |
|
| 10 | 10 | 11 | 11 |
|
| 15 | 15 | 14 | 14 |
|
| 15 | 14 | 17 | 12 |
|
| 16 | 15 | 16 | 14 |
|
| 15 | 14 | 13 | 14 |
|
| 19 | 20 | 23 | 21 |
Minimum inhibitory concentration (MIC) of novel compounds (µg/mL) against four microorganisms.
| Compound |
|
|
|
|
|---|---|---|---|---|
|
| 20 | 25 | 25 | 15 |
|
| 35 | 35 | 40 | 35 |
|
| 35 | 35 | 35 | 40 |
|
| 55 | 50 | 65 | 60 |
|
| 50 | 55 | 60 | 65 |
|
| 40 | 45 | 45 | 40 |
|
| 60 | 65 | 70 | 70 |
|
| 65 | 55 | 65 | 65 |
|
| 75 | 70 | 80 | 80 |
|
| 60 | 70 | 65 | 70 |
|
| 40 | 45 | 40 | 40 |
|
| 34 | 40 | 45 | 40 |
|
| 40 | 45 | 40 | 45 |
Cytotoxic activity of derivatives (µM) against human tumor cells.
| Compounds | In Vitro Cytotoxicity IC50 (µM) • | ||
|---|---|---|---|
| HePG-2 | HCT-116 | MCF-7 | |
|
| 4.50 ± 0.2 | 5.23 ± 0.3 | 4.17 ± 0.2 |
|
| 8.92 ± 0.6 | 8.22 ± 0.9 | 6.89 ± 0.4 |
|
| 9.94 ± 0.5 | 8.87 ± 0.7 | 7.83 ± 0.6 |
|
| 25.49 ± 1.7 | 21.43 ± 1.5 | 37.64 ± 1.2 |
|
| 24.48 ± 1.3 | 33.24 ± 2.2 | 23.47 ± 2.0 |
|
| 10.41 ± 1.1 | 12.66 ± 1.3 | 16.57 ± 1.5 |
|
| 36.57 ± 3.2 | 48.52 ± 2.9 | 26.13 ± 2.8 |
|
| 35.53 ± 2.6 | 24.43 ± 1.7 | 27.92 ± 1.6 |
|
| 53.54 ± 2.1 | 61.41 ± 2.8 | 69.33 ± 2.6 |
|
| 83.56 ± 4.1 | 71.13 ± 3.6 | 53.91 ± 3.5 |
|
| 18.52 ± 1.3 | 14.72 ± 1.1 | 17.90 ± 1.4 |
|
| 11.25 ± 1.4 | 19.54 ± 1.7 | 12.66 ± 1.5 |
|
| 30.75 ± 2.3 | 41.37 ± 2.5 | 35.11 ± 2.4 |
• IC50 (µM): 1–10 (very strong), 11–20 (strong), 21–50 (moderate), 51–100 (weak), and above 100 (non-cytotoxic); •• DOX: Doxorubicin.